BCAXBicara Therapeutics Inc.

HealthcareUSD
$24.70

The financials

Bicara Therapeutics Inc. by the numbers

Bicara Therapeutics Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$60M−$32Mn/a
Net income−$55M−$27Mn/a
Diluted EPS−$0.82−$0.50n/a

Biotechnology

Ranks #23 of 145 by Smart Score

Compare peers
ABSI+1.3%
Absci Corporation
ANAB+2.1%
AnaptysBio, Inc.
INVA-1.2%
Innoviva, Inc.
GHRS+3.0%
GH Research PLC
AKTS+8.5%
Aktis Oncology, Inc.
ZYME-2.2%
Zymeworks Inc.